Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) EP 0 769 553 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

- (43) Date of publication: 23.04.1997 Bulletin 1997/17
- (21) Application number: 96907679.3
- (22) Date of filing: 28.03.1996

- (51) Int. Cl.⁶: **C12N 15/11**, C12N 15/63, C12N 15/82, C12N 9/16
- (86) International application number: PCT/JP96/00812
- (87) International publication number: WO 96/30510 (03.10.1996 Gazette 1996/44)
- (84) Designated Contracting States:

 AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC

 NL PT SE
- (30) Priority: 29.03.1995 JP 96126/95
- (71) Applicant: Japan Tobacco Inc. Minato-Ku Tokyo 105 (JP)

- (72) Inventors:
 - MORIOKA, Shinji, Japan Tobacco Inc.
 Toyoda-cho, Iwata-gun, Shizuoka 438 (JP)
 - UEKI, Jun, Japan Tobacco Inc.
 Toyoda-cho, Iwata-gun, Shizuoka 438 (JP)
- (74) Representative: Ruffles, Graham Keith et al MARKS & CLERK, 57-60 Lincoln's Inn Fields London WC2A 3LS (GB)

(54) DNA FRAGMENT, RECOMBINATION VECTOR CONTAINING THE SAME, AND METHOD OF THE EXPRESSION OF ALIEN GENE WITH THE USE OF THE SAME

(57) A novel DNA which has a sequence different from those of publicly known DNAs capable of promoting the expression of an alien gene and can remarkably promote the expression of an alien gene. An isolated DNA fragment having a base sequence represented by SEQ ID NO:1 in the Sequence Listing; and an isolated

DNA fragment represented by this base sequence wherein one or more nucleotides have been added, inserted, deleted or replaced and having the effect of promoting the expression of a gene located in the downstream thereof.




Fig. 1

Description

5

10

20

35

40

45

55

TECHNICAL FIELD

The present invention relates to a novel DNA fragment having function to promote expression of genes, a vector containing the same and a method for expressing foreign genes using the same.

BACKGROUND ART

Promotion of expression of foreign genes is one of the most important techniques in applying genetic engineering processes to plants. One of the methods therefor is utilization of a DNA having a nucleotide sequence which promotes expression of a gene.

Known nucleotide sequences which promote expression of foreign genes include the intron of the catalase gene of castor bean (Japanese Laid-open Patent Application (Kokai) No. 3-103182; Tanaka et al., Nucleic Acids Res. 18, 6767-6770 (1990)). However, since there are wide varieties of plants to be manipulated and since promotion of expression of genes is required in each of the desired growth stages or tissues of organs, it is desired that wide varieties of DNAs which promote expression of genes can be utilized.

DISCLOSURE OF THE INVENTION

Accordingly, an object of the present invention is to provide a novel DNA, which can promote expression of foreign genes and which has a nucleotide sequence different from those of known DNAs that promote expression of foreign genes.

The present inventors intensively studied to discover introns of rice phospholipase D (hereinafter also referred to as "PLD") gene by comparing a rice cDNA and a rice genomic DNA, and discovered that one of the introns has a function to prominently promote expression of the gene downstream thereof, thereby completing the present invention.

That is, the present invention provides an isolated DNA fragment having a nucleotide sequence shown in SEQ ID NO. 1 in Sequence Listing or having a nucleotide sequence which is the same as the nucleotide sequence shown in SEQ ID NO. 1 in Sequence Listing except that one or a plurality of nucleotides are added, inserted, deleted or substituted, the latter nucleotide sequence having a function to promote expression of a gene downstream thereof. The present invention also provides a recombinant vector comprising the above-mentioned DNA fragment according to the present invention and a foreign gene to be expressed, which is operably linked to the DNA fragment at a downstream region of the DNA fragment. The present invention further provides a method for expressing a foreign gene comprising introducing the recombinant vector according to the present invention into host cells and expressing the foreign gene.

As experimentally confirmed in the Example described below, the DNA fragment according to the present invention largely promotes expression of the gene downstream of the DNA fragment. Therefore, it is expected that the present invention will largely contribute to expression of foreign genes by genetic engineering processes.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the important part of a genetic map of pBI221 into which the DNA fragment according to the present invention is inserted, which was prepared in the Example of the present invention.

BEST MODE FOR CARRING OUT THE INVENTION

As mentioned above, the DNA fragment according to the present invention has a nucleotide sequence shown in SEQ ID NO. 1 in the Sequence Listing. As will be described in detail in the Example below, introns located upstream of rice PLD gene were identified by comparing the nucleotide sequence of the cDNA of rice PLD gene and that of the rice genomic DNA. A fragment containing one of these intron sequences having a size of 173 bp located at the 5'-flanking region was prepared by PCR and the DNA fragment was inserted into an upstream site of a reporter gene of an expression vector containing the reporter gene. By checking the expression activity of the reporter gene, it was confirmed that the DNA fragment has a function to promote expression of the gene downstream thereof. The nucleotide sequence of the DNA fragment according to the present invention corresponds to 1661nt to 1843nt of the nucleotide sequence of the rice genomic PLD gene, which nucleotide sequence is shown in SEQ ID NO. 3 of the Sequence Listing.

The nucleotide sequence of the above-mentioned intron sequence having a size of 173 bp, which is located upstream of the rice PLD gene, is shown in SEQ ID NO. 4 in the Sequence Listing. Needless to say, the sequence shown in SEQ ID NO. 4 also has a function to promote expression of the gene downstream thereof. The nucleotide sequence shown in SEQ ID NO. 4 corresponds to 1666nt to 1838nt of the nucleotide sequence of the rice genomic PLD gene, which is shown in SEQ ID NO. 3 in the Sequence Listing.

Since the DNA fragment according to the present invention is an intron existing upstream of the rice PLD gene, and since its nucleotide sequence was determined according to the present invention, the DNA fragment may easily be prepared by PCR using the rice genomic DNA as a template. PCR is a conventional technique widely used in the field of genetic engineering and a kit therefor is commercially available, so that those skilled in the art can easily perform the PCR. One concrete example thereof is described in detail in the Example below.

It is well-known in the art that there are cases wherein the physiological activity of a physiologically active DNA sequence is retained even if the nucleotide sequence of the DNA is modified to a small extent, that is, even if one or more nucleotides are added, inserted, deleted or substituted. Therefore, DNA fragments having the same nucleotide sequence as shown in SEQ ID NO. 1 except that the DNA fragments have such modifications, which have the function to promote expression of the gene downstream thereof, are included within the scope of the present invention. That is, the DNA fragments having the same nucleotide sequence as shown in SEQ ID NO. 1 except that one or more nucleotides are added, deleted or substituted, which have the function to promote expression of the gene downstream thereof, are included within the scope of the present invention. Particularly, in the nucleotide sequence shown in SEQ ID NO. 1, the 5 nucleotides at the 5'-end and the 6 nucleotides at the 3'-end are the nucleotides in the exon regions, so that it is thought that the nucleotide sequences which do not have these regions also have the function to promote gene expression. Thus, these DNA fragments are within the scope of the present invention.

Modification of DNA which brings about addition, deletion or substitution of the amino acid sequence encoded thereby can be attained by the site-specific mutagenesis which is well-known in the art (e.g., Nucleic Acid Research, Vol. 10, No. 20, p6487-6500, 1982). In the present specification, "one or a plurality of nucleotides" means the number of nucleotides which can be added, deleted or substituted by the site-specific mutagenesis.

Site-specific mutagenesis may be carried out by, for example, using a synthetic oligonucleotide primer complementary to a single-stranded phage DNA except that the desired mutation as follows. That is, using the above-mentioned synthetic oligonucleotide as a primer, a complementary chain is produced by a phage, and host bacterial cells are transformed with the obtained double-stranded DNA. The culture of the transformed bacterial cells is plated on agar and plaques are formed from a single cell containing the phage. Theoretically, 50% of the new colonies contain the phage having a single-stranded chain carrying the mutation and remaining 50% of the colonies contain the phage having the original sequence. The obtained plaques are then subjected to hybridization with a kinase-treated synthetic probe at a temperature at which the probe is hybridized with the DNA having exactly the same sequence as the DNA having the desired mutation but not with the original DNA sequence that is not completely complementary with the probe. Then the plaques in which the hybridization was observed are picked up, cultured and the DNA is collected.

In addition to the above-mentioned site-specific mutagenesis, the methods for substituting, deleting or adding one or more amino acids without losing the function include a method in which the gene is treated with a mutagen and a method in which the gene is selectively cleaved, a selected nucleotide is removed, added or substituted and then the gene is ligated.

The DNA fragment according to the present invention has a function to promote expression of the gene downstream thereof. Therefore, by inserting the DNA fragment according to the present invention into the transcriptional region of a desired foreign gene to be expressed, preferably into the 5'-end region of the transcriptional region, expression of the foreign gene is promoted. The method for expressing a foreign gene has already been established in the field of genetic engineering. That is, by inserting the desired foreign gene into a cloning site of an expression vector, introducing the resulting vector into host cells and expressing it, the foreign gene may be expressed. According to the method of the present invention, the DNA fragment according to the present invention is inserted at a site upstream of the foreign gene in a manner such that the DNA fragment is operably linked to the foreign gene, and the foreign gene is expressed. The term that the DNA fragment according to the present invention is "operably linked" to the foreign gene means that expression of the foreign gene is detectably increased by inserting the DNA fragment according to the present invention when compared with the case wherein the DNA fragment according to the present invention is not inserted. The DNA according to the present invention may be inserted into the site immediately upstream of the foreign gene. Alternatively, another sequence may be located between the DNA according to the present invention and the foreign gene. Although the size of this intervening sequence is not restricted, it usually has a size of 0 - 1000 bp. A promoter sequence is located upstream of the DNA fragment according to the present invention. The DNA fragment according to the present invention may be inserted into the site immediately downstream of the promoter, or another sequence may be located between the promoter and the DNA according to the present invention. Although the size of this intervening sequence is not restricted, it is usually 0 - 1000 bp. In summary, all recombinant vectors with which the expression of the foreign gene is detectably increased by inserting the DNA fragment according to the present invention when compared with the case wherein the DNA fragment is not inserted, are within the scope of the present invention.

Since the nucleotide sequence of the cloning site of an expression vector is known, the DNA fragment according to the present invention may easily be inserted into the vector.

Wide varieties of such an expression vector are well-known in the art and are commercially available. These expression vectors contain at least a replication origin for replication in the host cells, a promoter, a cloning site giving a restriction site for inserting the foreign gene, and a selection marker such as drug resistance, and usually contain a

55

terminator which stably terminates transcription, and an SD sequence when the host is a bacterium. In the method of the present invention, any of these known expression vectors may be employed.

Example

5

10

15

25

30

40

The present invention will now be described in more detail by way of examples thereof. However, the present invention is not restricted to the examples.

1. Purification of PLD of Rice Bran

For purification, a reference (Takano et al., Journal of Japan Food Industry Association, 34, 8-13 (1987) was referred. The enzyme activity was measured by employing phosphatidylcholine as a substrate and quantifying the choline generated by the enzyme reaction (Imamura et al., J. Biochem. 83, 677-680 (1978)). It should be noted, however, the enzyme reaction was stopped by heat treatment at 95°C for 5 minutes.

That is, to 100 g of bran of rice (*Oryza sativa*), variety "KOSHIHIKARI", one liter of hexane was added and the mixture was stirred for a whole day and night, thereby defatting the rice bran. To the resultant, 10 g of Polycral AT (trademark, polyvinylpyrrolidone, commercially available from GAF Chemical) and 500 ml of 10 mM Tris-HCl buffer (pH7) containing 1 mM CaCl₂ and 5 mM 2-mercaptoethanol were added, and the resulting mixture was stirred for 1 hour to extract the enzyme. The extract was filtered through an 8-layered gauze and the filtrate was centrifuged at 15,000 x g for 20 minutes, followed by recovering the middle layer as a crude extract. The crude extract was treated with ammonium sulfate (65% saturation) and the generated precipitates were collected by centrifugation (15,000 x g, 20 minutes), followed by dialyzing the precipitates after dissolution against the above-mentioned buffer. After the dialysis, precipitates were eliminated by filtration to obtain ammonium sulfate fraction.

The ammonium sulfate fraction was applied to a column (2.0 x 10 cm) of DEAE-Cellulose (commercially available from Whattman) equilibrated with buffer A (10 mM Tris-HCl, pH 7, 1 mM CaCl₂, 1 mM 2-mercaptoethanol). After washing the column with about 100 ml of buffer A containing 50 mM NaCl, elution was carried out with 120 ml of buffer A having a linear gradient of NaCl concentration from 50 mM to 350 mM. PLD was eluted at a NaCl concentration of about 0.2 M. The fraction having PLD activity was collected as an eluted solution (DEAE-cellulose).

To the eluted solution (DEAE-cellulose), 3 M ammonium sulfate was added in an amount attaining the final concentration of ammonium sulfate of 1 M, and the resulting mixture was applied to a Phenyl Sepharose column (commercially available from Pharmacia, 2.6 x 10 cm) equilibrated with buffer A containing 1 M ammonium sulfate. Elution was performed using 240 ml of buffer A having a linear gradient of ammonium sulfate concentration from 1.0 M to 0 M. PLD was eluted at a concentration of ammonium sulfate of about 0.1 M. The fraction having the activity was recovered and dialyzed against buffer A to obtain an eluted solution (Phenyl Sepharose).

The eluted solution (Phenyl Sepharose) was applied to Mono Q column (anion-exchange column commercially available from Pharmacia, 16 x 10 cm) equilibrated with buffer A, and elution was performed using 150 ml of buffer A having a gradient of NaCl concentration from 50 mM to 350 mM. PLD was eluted at NaCl concentration from 210 mM to 235 mM. The fraction having PLD activity was recovered and dialyzed against buffer A to obtain an eluted solution (Mono Q 1st).

The eluted solution (Mono Q 1st) was concentrated to 0.5 ml by ultrafiltration and applied to Superose 6 column (commercially available from Pharmacia, 1.0 x 30 cm equilibrated with buffer A containing 0.1 M NaCl and elution was performed using the same buffer. The molecular weight of PLD was estimated to be 78 kDa. The fraction having PLD activity was recovered as an eluted solution (Superose 6).

To the eluted solution (Superose 6), 2.5 ml of 40% Carrier Ampholite (commercially available from Pharmacia, pH4.0-6.0) and distilled water were added to attain a final volume of 50 ml and isoelectric electrophoresis was carried out using Rotofore (commercially available from Biorad). Electrophoresis was performed at 2°C with a constant power of 12W for 4 hours. PLD activity was observed at about pH 4.9. The fraction having PLD activity was collected and dialyzed against buffer A to obtain an isoelectric electrophoresis fraction.

The isoelectric electrophoresis fraction was applied to Mono Q column (commercially available from Pharmacia, 0.5 x 5 cm) and eluted with NaCl having a linear gradient of concentration of 50 mM to 350 mM. PLD was eluted at NaCl concentrations of about 210 mM and about 235 mM. The two fractions having PLD activity were recovered as eluted solutions (Mono Q 2nd-I, II).

Purities of the eluted solutions (Mono Q 2nd-I, II) were checked by SDS-polyacrylamide electrophoresis (Laemmli (1970)) using 7.5% acrylamide. After the electrophoresis, the gel was stained with Coomassie brilliant blue R-250. With either eluted solution, a main band was observed at a position corresponding to a molecular weight of 82 kDa. With the eluted solution (Mono Q 2nd-II), only a single band was observed.

By the purification described above, the purification magnifications of the eluted solutions (Mono Q 2nd-I, II) were 380 times and 760 times, respectively, with respect to the crude extract.

Properties of the enzymes contained in the two fractions were determined. The results are shown in Table 1. The

buffer solutions used for the measurement of the optimum pH were sodium acetate (pH 4-6), MES-NaOH (pH 5.5-7.0) and Tris-HCI (pH 7-9), all of which have a concentration of 100 mM in all of the buffer solutions. The pH stability means the pH range in which decrease in the enzyme activity is not observed after leaving the enzyme at the respective pH at 25°C for 30 minutes. The temperature stability was measured by measuring the remaining activity after leaving the enzyme to stand at 4°C, 25°C, 37°C or 50°C for 30 minutes. The substrate specificity was measured at a substrate concentration of 5 mM and expressed in terms of the relative activity taking the enzyme activity to phosphatidylcholine as 100.

Table 1

	Mono Q 2nd-I	Mono Q 2nd-II
Km Value	0.29 mM	0.29 mM
Optimum pH	6	6
pH Stability	7-8	7-8
Temperature Stability	4-37°C	4-37°C
Ca ²⁺ Dependency	not less than 20 mM	not less than 20 mM
Substrate Specificity		
Phosphatidylcholine	100	100
Lysophosphatidylcholine	13	12
Sphingomyelin	6	4

2. Proof that Purified Protein is PLD

10

15

20

25

30

Each of the eluted solutions (Mono Q 2nd-I, II) was subjected to SDS-polyacrylamide gel electrophoresis in the same manner as in the purity test, and the obtained patterns were transferred to PVDF membranes (commercially available from Millipore), followed by staining the membranes. The band of the protein having the molecular weight of 82 kDa was cut out and the amino acid sequence of the N-terminal region of the protein was determined by a protein sequencer (commercially available from Shimazu Seisakusho, PSQ-1). For both proteins, amino acid sequence up to 10 residues from the N-terminal could be determined, and the determined sequences were identical. The sequence was as follows. Val Gly Lys Gly Ala Thr Lys Val Tyr Ser

Although the relationship between the proteins having the molecular weight of 82 kDa contained in the two fractions having the enzyme activity is not clear, it is thought that they have high homology in their amino acid sequences, so that it was judged that there would be no problem even if a mixture of the fractions is used as an antigen for preparing an antibody.

A mixture of the eluted solutions (Mono Q 2nd-I, II) was subjected to SDS-polyacrylamide gel electrophoresis using 7.5% acrylamide, and the gel was stained with Coomassie brilliant blue R-250. The band of the protein having the molecular weight of 82 kDa was cut out and recovered by electroelution (25 mM Tris, 192 mM glycine, 0.025% SDS, 100V, 10 hours). Then SDS was removed by electrodialysis (15 mM ammonium bicarbonate, 200 V, 5 hours) and the resultant was lyophilized. For the electroelution and electrodialysis, BIOTRAP (commercially available from Schleicher & Schuell) was used.

The protein having the molecular weight of 82 kDa highly purified by the above-described method was administered to a rabbit in an amount of 50 μ g per time at 7 days' intervals. Immunological titration test was performed for the sera before the immunization and after the third immunization. To the PLD solution containing 8.6 x 10^{-3} units of PLD, were added 0 - 50 μ l of the serum before the immunization or after the third immunization, 50 μ l of 250 mM Tris-HCl (pH7.0), 5 μ l of 50 mM CaCl₂, 50 μ l of 0.2% Triton X-100 (trademark) and water to a total volume of 250 μ l, and the mixture was left to stand at room temperature for 2.5 hours. To the resultant, 200 μ l of Protein A Sepharose (commercially available from Pharmacia) was added and the resulting mixture was gently shaken at room temperature for 2 hours. The mixture was then centrifuged (500 x g, 5 minutes) and the enzyme activity in the supernatant was measured. Taking the measured enzyme activity in the case where the serum was not added as 100%, the enzyme activities in cases where 20 μ l and 50 μ l of the serum before immunization were added were 95% and 88%, respectively, and the enzyme activities in cases where 20 μ l and 50 μ l of the serum after the third immunization were added were 75% and 30%, respectively. These results prove that the protein having the molecular weight of 82 kDa is PLD.

3. Determination of Amino Acid Sequence of Internal Regions

The PLD protein was fragmentated in a gel (Cleveland et al., J. Biol. Chem., 252, 1102(1977)). The cut out gel containing the PLD protein was inserted into a stacking gel well on a 15% acrylamide gel prepared for separation of peptides, and *Staphylococcus aureus* V8 protease (commercially available from Wako Pure Chemical Industries, Ltd) in an amount of 1/10 volume of the PLD protein was overlaid, followed by starting electrophoresis. The electrophoresis was stopped at the time point at which the bromophenol blue reached the center of the stacking gel and then restarted 30 minutes later. After the electrophoresis, the pattern was transferred to a PVDF membrane and the membrane was stained. Clear bands were observed at the positions corresponding to molecular weights of 20, 14, 13, 11 and 10 kDa. Each of the bands of the peptide fragments having molecular weights of 20, 14 and 13 kDa were cut out and their amino acid sequences were determined by a protein sequencer. The determined sequences are as follows.

20 kDa Asn Tyr Phe His Gly Ser Asp Val Asn ? Val Leu ? Pro Arg Asn Pro Asp Asp(Asp) ? ? Ile

14 kDa Thr ? Asn Val Gin Leu Phe Arg Ser lie Asp Gly Gly Ala Ala Phe Gly Phe Pro Asp Thr Pro Glu Glu Ala Ala Lys ? Gly Leu Val Ser Gly

13 kDa Ile Ala Met Gly Gly Tyr Gln Phe Tyr His Leu Ala Thr Arg Gln Pro Ala Arg Gly Gln Ile His Gly Phe Arg Met Ala Leu ? Tyr Glu His Leu Gly Met Leu ? Asp Val Phe

(In the sequences, "?" means the amino acid residue which could not be identified, and the amino acid residue in parentheses means that the amino acid residue could not be identified confidentially.

4. Preparation of cDNA Library of Rice Immature Seeds

Total RNAs were extracted from immature seeds obtained after 5 days from flowering by the SDS-phenol method, and prepared by the lithium chloride precipitation. Poly(A)*RNA was prepared using Oligotex-dT30 (commercially available from Takara Shuzo) according to the instructions provided by the manufacturer. For the cDNA cloning, cDNA synthesis System Plus (commercially available from Amersham) and cDNA Cloning System Agt10 (commercially available from Amersham) were used. However, \(\lambda ZAPII\) vector (commercially available from Stratagene) was used as the cloning vector and XL1-Blue was used as the host cells.

5. Preparation of Probes

15

30

Oligonucleotides corresponding to the amino acid sequences of PLD were synthesized by a DNA synthesizer (commercially available from Applied Biosystems). The sequences thereof as well as the corresponding amino acid sequences are as follows.

20KF 5' AAYTAYTTYCAYGG 3' 20KR1 5' RTCRTCRTCNGGRTT 3'

(In these sequences, "R" represents a purine base A or G; "Y" represents a pyrimidine base T or G; and N represents G, A, T or C.)

The 20KF is a mixture of 32 kinds of oligonucleotides containing the DNA sequences encoding the amino acid sequence of

Asn Tyr Phe His Gly

found in a peptide having a molecular weight of 20 kDa, and the 20KR1 is a mixture of 128 kinds of oligonucleotides containing complementary chains of the DNA sequences encoding the amino acid sequence of

Asn Pro Asp Asp(Asp)

found in the same peptide.

The cDNA synthesis was carried out using 10 ng of Poly(A)+RNA, 0.3 µg of random hexamer (N6), 10 U of an RNase inhibitor (RNA Guard, commercially available from Pharmacia), 1 mM each of dATP, dCTP, dGTP and dTTP, 1 x PCR buffer (commercially available from Takara Shuzo), 50 mM of magnesium chloride and 100 U of a reverse transcriptase (M-MuLV RTase, commercially available from BRL) in a total volume of 10 µl. The reaction was carried out at 37°C for 30 minutes and the reaction mixture was then heated at 95°C for 5 minutes, followed by retaining the reaction mixture in ice.

Polymerase chain reaction (PCR) was performed using the above-described cDNA as a template and 20KF and 20KR1 as primers. The reaction was performed using 10 μ l of the cDNA synthesis reaction mixture, a mixture of 50 pmol each of the primers, 200 μ M each of dATP, dCTP, dGTP and dTTP, 1 x PCR buffer (commercially available from TAKARA SHUZO), and 2.5 U of AmpliTaq DNA polymerase (commercially available from TAKARA SHUZO) in a total volume of 50 μ l. A cycle of temperature conditions of 94°C for 1 minute, 40°C for 1 minute and 72°C for 2.5 minutes was

repeated 30 times in a DNA Thermocycler (commercially available from Perkin Elmer Cetus).

The PCR product was separated on 2% agarose gel. A small number of fragments were detected by the ethidium bromide staining method. One of them had a size of 94 bp as expected.

The PCR fragment was cut out from the gel and subcloned into pUC19 plasmid. The DNA sequence of the subcloned PCR fragment was determined by the dideoxy method using T7 sequencing kit (commercially available from Pharmacia). Between the two primers, a DNA sequence encoding the expected amino acid sequence was observed. The nucleotide sequence of the DNA between the primers and the amino acid sequence encoded thereby are as follows.

10 C TCT GAC GTG AAC TGT GTT CTA TGC CCT CGC Ser Asp Val Asn Cys Val Leu Cys Pro Arg

Isotope ³²P (commercially available from Amersham) was incorporated into the oligonucleotide using a DNA 5'-end labelling kit MEGALABEL (commercially available from Takara Shuzo) to obtain a radioactive oligonucleotide probe.

6. Screening of PLD Gene-containing Clones

15

25

40

50

55

Using the radioactive oligonucleotide as a probe, a cDNA library was screened. Hybridization solution contained 0.5 M sodium phosphate buffer (pH 7.2), 7% SDS, 1 mM EDTA and 100 µg/ml of salmon sperm DNA, and hybridization was performed after adding the probe to the hybridization solution at 45°C for 16 hours. The washing solution contained 0.3 M NaCl and 30 mM sodium citrate, and washing was performed twice at 45°C for 20 minutes each. Positive plaques were isolated and subcloned *in vivo* into pBluescript plasmid (commercially available from Stratagene) in accordance with the instructions provided by the manufacturer of λ ZAPII cloning vector. The nucleotide sequence was determined by the dideoxy method. As a result, a region encoding the internal amino acid sequence determined in the "Section 3" existed.

7. Determination of Nucleotide Sequence of 5'-end Region

Since a clone containing the full length of cDNA could not be isolated, a DNA fragment having the 5'-end region was prepared by RACE method (Edwards et al., Nucleic Acids Res., 19, 5227-5232 (1991)). 5'-AmpliFINDER RACE Kit (commercially available from Clonetech) was used in accordance with the manual attached to the product. An oligoDNA was synthesized based on the nucleotide sequence of the cDNA determined in "Section 6", and PCR was performed using the mRNA prepared by the method described in "Section 4" as a template. The PCR product was subcloned into a PCRII vector (commercially available from Invitrogen) and the nucleotide sequence was determined by the dideoxy method. The thus determined nucleotide sequence of the cDNA of rice PLD as well as the deduced amino acid sequence encoded thereby is shown in SEQ ID NO. 2 in the Sequence Listing. It is thought that translation is initiated from the 182nd nucleotide shown in SEQ ID NO. 2 since a termination codon exists at 36 bases upstream thereof.

8. Isolation of PLD Genomic Clone Corresponding to PLD cDNA and Identification of Promoter Region

To isolate a genomic DNA clone having the regulatory sequence of the PLD gene corresponding to the PLD cDNA determined in "section 6", which was cloned into pBluescript plasmid, a genomic library of rice, variety "KOSHIHIKARI" was prepared. This was carried out by partially digesting DNAs from live leaves of KOSHIHIKARI with *Mbo* I, purifying a fraction having a size of 16 - 20 kb by sucrose gradient centrifugation, and using lambda DASH II (commercially available from Stratagene) and GigapackII Gold (commercially available from Stratagene). The genomic library was screened with the PLD cDNA clone as a probe. The screening was carried out in the same manner as in "Section 6" except that hybridization was performed at 65°C for 16 hours, the washing solution contained 0.5 x SSC and 0.1% SDS, and that the washing was performed twice at 65°C for 20 minutes each. The nucleotide sequence of the hybridized genomic clone was determined by the dideoxy method. As a result, a region homologous to the cDNA sequence determined in "Section 6" existed.

The transcription initiation site was determined by the method described in "Section 7". In the vicinity of the transcription initiation site, a "TATA" consensus sequence box was observed. The ATG translation initiation site was determined based on the determined DNA sequence as the most upstream ATG codon in the translation open reading frame of the clone and as the ATG codon which is first accessible in the mRNA synthesized in rice.

The DNA sequence of a part of the genomic clone hybridized with the cDNA clone is shown in SEQ ID NO. 3. In the genomic DNA sequence, an open reading frame starting from the ATG translation initiation codon, which overlaps with the corresponding cDNA sequence has been identified. The promoter region exists upstream of the ATG translation initiation codon and starts from the site immediately upstream thereof.

9. Identification of Introns and Analysis of Functions thereof on Expression of Genes

From comparison between the cDNA (SEQ ID NO. 2) and the genomic DNA (SEQ ID NO. 3), it was proved that 3 introns exist in PLD gene. Among these, the intron having a size of 173 bp located at the 5'-flanking region of the mRNA (i.e., the nucleotide sequence between 1666nt and 1838nt of the nucleotide sequence shown in SEQ ID NO. 3, the sequence being shown in SEQ ID NO. 4) was tested for its influence on expression of a gene in plant cells. Primers of 15mer each of which contains 5 bases of exon region (5'-ACCCGGTAAGCCCAG-3', 3'-CCCCGGGTCCATCC-5') were synthesized and PCR was carried out using the genomic clone as a template according to the method described in the Section of "5. Preparation of Probes". The PCR product was subcloned into PCRII vector and a fragment was cut out with Eco RI. The fragment was blunted and inserted into the Sma I site of a plasmid pBI221 (commercially available from Toyobo) (see Fig. 1). The obtained recombinant plasmid was introduced into rice cultured cells (Baba et al., Plant Cell Physiol. 27, 463-471 (1986)) in accordance with the reported method (Shimamoto et al., Nature, 338, 274-27.6 (1989)) and β-glucuronidase (GUS) activity was measured. As shown in Table 2, by introducing the intron, the GUS activity was increased. Further, as shown in Table 3, increase in the GUS activity was also observed in the case where the intron was inserted in the reverse direction. The direction of the intron was determined based on the sizes of the fragments cut out with Bg/ II and Bam HI, utilizing the Bg/ II site existing in the intron sequence and the Bam HI site existing in pBl221.

20

Table 2

Plasmid	GUS Activity
pBl221	10.4
pBl221 + intron	105.7
(pmol MU/min /mo	protein)

30

25

35

40

45

50

55

Table 3

Plasmid	GUS Activity
pBl221	8.8
pBl221 + intron	79.4
pBl221 + intron (reverse direction)	54.2
(pmol MU/min./mg protein)	

	SEQUENCE LISTING	
_	SEQ ID NO.: 1	
5	SEQUENCE LENGTH: 183	
	SEQUENCE TYPE: Nucleic Acid	
10	MOLECULE TYPE: Genomic DNA	
	ORIGINAL SOURCE	
	ORGANISM: Oryza sativa	
15	SEQUENCE DESCRIPTION	
	ACCCGGTAAG CCCAGTGTGC TTAGGCTAAG CGCACTAGAG CTTCTTGCTC GCTTGCTTCT	60
20	TCTCCGCTCA GATCTGCTTG CTTGCTTGCT TCGCTAGAAC CCTACTCTGT GCTGCGAGTG	120
	TCGCTGCTTC GTCTTCCTTC CTCAAGTTCG ATCTGATTGT GTGTGTGGGG GGGCGCAGGT	180
	AGG	183
25	SEQ ID NO.: 2	
	SEQUENCE LENGTH: 3040	
	SEQUENCE TYPE: Nucleic Acid	
30	MOLECULE TYPE: cDNA to mRNA	
	ORIGINAL SOURCE	
35	ORGANISM: Oryza sativa	
	SEQUENCE DESCRIPTION	
	AGTCTCTCTT CTCCCGCAAT TTTATAATCT CGATCGATCC AATCTGCTCC CCTTCTTCTT	60
10	CTACTCTCCC CATCTCGGCT CTCGCCATCG CCATCCTCCT CTCCCTTCCC GGAGAAGACG	120
	CCTCCCTCCG CCGATCACCA CCCGGTAGGG CGAGGAGGGA GCCAAATCCA AATCAGCAGC	180
5	C ATG GCG CAG ATG CTG CTC CAT GGG ACG CTG CAC GCC ACC ATC TTC GAG	229
	Met Ala Gln Met Leu Leu His Gly Thr Leu His Ala Thr Ile Phe Glu	
	1 5 10 15	
0	GCG GCG TCG CTC TCC AAC CCG CAC CGC GCC AGC GGA AGC GCC CCC AAG	277
	Ala Ala Ser Leu Ser Asn Pro His Arg Ala Ser Gly Ser Ala Pro Lys	

				20					25					30			
	TTC	ATC	CGC	AAG	TTT	GTG	GAG	GGG	ATT	GAG	GAC	ACT	GTG	GGT	GTC	GGC	325
5	Phe	He	Arg	Lys	Phe	Vai	Glu	Gly	He	Glu	Asp	Thr	Val	Gly	Val	Gly	
			35					40					45				
10	AAA	GGC	GCC	ACC	AAG	GTG	TAT	TCT	ACC	ATT	GAT	CTG	GAG	AAA	GCT	CGT	373
,,,	Lys	Gly	Ala	Thr	Lys	Val	Tyr	Ser	Thr	lle	Asp	Leu	Glu	Lys	Ala	Arg	
		50					55					60					
15	GTA	GGG	CGA	ACT	AGG	ATG	ATA	ACC	AAT	GAG	ccc	ATC	AAC	CCT	CGC	TGG	421
	Val	Gly	Arg	Thr	Arg	Met	He	Thr	Asn	Glu	Pro	He	Asn	Pro	Arg	Trp	
	65					70					75					80	
?0	TAT	GAG	TCG	TTC	CAC	ATC	TAT	TGC	GCT	CAT	ATG	GCT	TCC	AAT	GTG	ATC	469
	Tyr	Glu	Ser	Phe	His	lle	Tyr	Cys	Ala	His	Met	Ala	Ser	Asn	Val	lle	
ne .					85					90					95		
25	TTC	ACT	GTC	AAG	ATT	GAT	AAC	CCT	ATT	GGG	GCA	ACG	AAT	ATT	GGG	AGG	517
	Phe	Thr	Val	Lys	He	Asp	Asn	Pro	lle	Gly	Ala	Thr	Asn	He	Gly	Arg	
o				100					105					110			
	GCT	TAC	CTG	CCT	GTC	CAA	GAG	CTT	CTC	AAT	GGA	GAG	GAG	ATT	GAC	AGA	565
	Ala	Tyr	Leu	Pro	Val	Gln	Glu	Leu	Leu	Asn	Gly	Glu	Glu	He	Asp	Arg	
5			115					120					125				
	TGG	CTC	GAT	ATC	TGT	GAT	AAT	AAC	CGC	GAG	TCT	GTT	GGT	GAG	AGC	AAG	613
	Trp	Leu	Asp	He	Cys	Asp	Asn	Asn	Arg	Glu	Ser	Val	Gly	Glu	Ser	Lys	
0		130					135					140					
	ATC	CAT	GTG	AAG	CTT	CAG	TAC	TTC	GAT	GTT	TCC	AAG	GAT	CGC	AAT	TGG	661
5	He	His	Val	Lys	Leu	Gln	Tyr	Phe	Asp	Val	Ser	Lys	Asp	Arg	Asn	Trp	
	145					150					155					160	
	GCG	AGG	GGT	GTC	CGC	AGT	ACC	AAG	TAT	CCA	GGT	GTT	CCT	TAC	ACC	TTC	709
,	Ala	Arg	Gly	Val	Arg	Ser	Thr	Lys	Tyr	Pro	Gly	Val	Pro	Tyr	Thr	Phe	
					165					170					175		

	TTC	TCT	CAG	AGG	CAA	GGG	TGC	AAA	GTT	ACC	TTG	TAC	CAA	GAT	GCT	CAT	757
_	Phe	Ser	Gln	Arg	Gln	Gly	Cys	Lys	Val	Thr	Leu	Tyr	Gln	Asp	Ala	His	
5				180					185					190			
	GTC	CCA	GAC	AAC	TTC	ATT	CCA	AAG	ATT	CCG	CTT	GCC	GAT	GGC	AAG	AAT	805
10	Val	Pro	Asp	Asn	Phe	He	Pro	Lys	1 l e	Pro	Leu	Ala	Asp	Gly	Lys	Asn	
			195					200					205				
	TAT	GAA	CCC	CAC	AGA	TGC	TGG	GAG	GAT	ATC	TTT	GAT	GCT	ATA	AGC	AAT	853
15	Tyr	Glu	Pro	His	Arg	Cys	Trp	Glu	Asp	He	Phe	Asp	Ala	He	Ser	Asn	
		210					215					220					
	GCT	CAA	CAT	TTG	ATT	TAC	ATC	ACT	GGC	TGG	TCT	GTA	TAC	ACT	GAG	ATC	901
20	Ala	GIn	His	Leu	He	Tyr	He	Thr	Gly	Trp	Ser	Val	Tyr	Thr	Glu		
	225					230					235					240	
25					GAC												949
	Thr	Leu	Val	Arg	Asp	Ser	Asn	Arg	Pro	Lys	Pro	Gly	Gly	Asp		Thr	
					245					250					255		
30					CTC												997
	Leu	Gly	Glu	Leu	Leu	Lys	Lys	Lys	Ala	Ser	Glu	Gly	Val		Val	Leu	
				260					265					270			
35					GAT												1045
	Met	Leu		Trp	Asp	Asp	Arg		Ser	Val	Gly	Leu			Arg	Asp	
40			275					280					285			000	1000
40					ACA												1093
	Gly			Ala	Thr	His		Glu	Glu	Thr	Glu			Phe	HIS	Gly	
45		290					295					300		0.4.0	T 04	000	1141
					TGT												1141
			Val	Asn	Cys		Leu	Cys	Pro	Arg			Asp	ASP	Ser		
50	305					310					315			0.4.0	04*	320	1100
	AGC	ATT	GTT	CAG	GAT	CTG	TCG	ATC	TCA	ACT	ATG	TIT	ACA	CAC	GAI	CAG	1189

	Ser	Пе	Val	Gin	Asp	Leu	Ser	He	Ser	Thr	Met	Phe	Thr	His	His	Gln	
-					325					330					335		
5	AAG	ATA	GTA	GTT	GTT	GAC	CAT	GAG	TTG	CCA	AAC	CAG	GGC	TCC	CAA	CAA	1237
	Lys	lle	Val	Val	Val	Asp	His	Glu	Leu	Pro	Asn	Gln	Gly	Ser	Gln	Gin	
10				340					345					350			
	AGG	AGG	ATA	GTC	AGT	TTC	GTT	GGT	GGC	CTT	GAT	CTC	TGT	GAT	GGA	AGG	1285
	Arg	Arg	lle	Val	Ser	Phe	Val	Gly	Gly	Leu	Asp	Leu	Cys	Asp	Gly	Arg	
15			355					360					365				
	TAT	GAC	ACT	CAG	TAC	CAT	TCT	TTG	TTT	AGG	ACA	CTC	GAC	AGT	ACC	CAT	1333
	Tyr	Asp	Thr	Gln	Tyr	His	Ser	Leu	Phe	Arg	Thr	Leu	Asp	Ser	Thr	His	
20		370					375					380					
	CAT	GAT	GAC	TTC	CAC	CAG	CCA	AAC	TTT	GCC	ACT	GCA	TCA	ATC	AAA	AAG	1381
25	His	Asp	Asp	Phe	His	Gln	Pro	Asn	Phe	Ala	Thr	Ala	Ser	lle	Lys	Lys	
	385					390					395					400	
	GGT	GGA	CCT	AGA	GAG	CCA	TGG	CAT	GAT	ATT	CAC	TCA	CGG	CTG	GAA	GGG	1429
30	Gly	Gly	Pro	Arg	Glu	Pro	Trp	His	Asp	lie	His	Ser	Arg	Leu	Glu	Gly	
					405					410					415		
	CCA	ATC	GCA	TGG	GAT	GTT	CTT	TAC	AAT	TTC	GAG	CAG	AGA	TGG	AGA	AAG	1477
35	Pro	Пe	Ala	Trp	Asp	Val	Leu	Tyr	Asn	Phe	Glu	Gln	Arg	Trp	Arg	Lys	
				420					425					430			
	CAG	GGT	GGT	AAG	GAT	CTC	CTT	CTG	CAG	CTC	AGG	GAT	CTG	TCT	GAC	ACT	1525
10	Gln	Gly	Gly	Lys	Asp	Leu	Leu	Leu	GIn	Leu	Arg	Asp	Leu	Ser	Asp	Thr	
			435					440					445				
5	ATT	ATT	CCA	CCT	TCT	CCT	GTT	ATG	TTT	CCA	GAG	GAC	AGA	GAA	ACA	TGG	1573
	lle	He	Pro	Pro	Ser	Pro	Val	Met	Phe	Pro	Glu	Asp	Arg	Glu	Thr	Trp	
		450					455					460					
o	AAT	GTT	CAG	CTA	TTT	AGA	TCC	ATT	GAT	GGT	GGT	GCT	GCT	TTT	GGG	TTC	1621
	Asn	Val	Gin	Leu	Phe	Arg	Ser	He	Asp	Gly	Gly	Ala	Ala	Phe	Gly	Phe	

	465					470					475					480	
5	CCT	GAT	ACC	CCT	GAG	GAG	GCT	GÇA	AAA	GCT	GGG	CTT	GTA	AGC	GGA	AAG	1669
5	Pro	Asp	Thr	Pro	Glu	Glu	Ala	Ala	Lys	Ala	Gly	Leu	Val	Ser	Gly	Lys	
					485					490					495		
10	GAT	CAA	ATC	ATT	GAC	AGG	AGC	ATC	CAG	GAT	GCA	TAC	ATA	CAT	GCC	ATC	1717
	Asp	Gln	lle	lle	Asp	Arg	Ser	He	Gln	Asp	Ala	Tyr	He	His	Ala	He	
				500					505					510			
15	CGG	AGG	GCA	AAG	AAC	TTC	ATC	TAT	ATA	GAG	AAC	CAA	TAC	TTC	CTT	GGA	1765
	Arg	Arg	Ala	Lys	Asn	Phe	lle	Tyr	lle	Glu	Asn	Gln	Tyr	Phe	Leu	Gly	
			515					520					525				
20	AGT	TCC	TAT	GCC	TGG	AAA	CCC	GAG	GGC	ATC	AAG	CCT	GAA	GAC	ATT	GGT	1813
	Ser	Ser	Tyr	Ala	Trp	Lys	Pro	Glu	Gly	Пe	Lys	Pro	Glu	Asp	He	Gly	
25		530					535					540					
	GCC	CTG	CAT	TTG	ATT	CCT	AAG	GAG	CTT	GCA	CTG	AAA	GTT	GTC	AGT	AAG	1861
	Ala	Leu	His	Leu	He	Pro	Lys	Glu	Leu	Ala	Leu	Lys	Val	Val	Ser	Lys	
30	545					550					555					560	
															ATG		1909
	He	Glu	Ala	Gly	Glu	Arg	Phe	Thr	Val	Tyr	Val	Val	Val	Pro	Met	Trp	
35					565					570					575		
															GAC		1957
40	Pro	Glu	Gly	Val	Pro	Glu	Ser	Gly		Val	Gln	Ala	He		Asp	Trp	
				580					585					590		070	0005
							•									CTC	2005
45	Gln	Arg	Arg	Thr	Met	Glu	Met			Thr	Asp	lie		Glu	Ala	Leu	
			595					600					605				0050
																TTC	2053
50	Gln	Ala	Lys	Gly	He	Glu		Asn	Pro	Lys	Asp			Ihr	Phe	Phe	
		610					615					620					

	TGC	TTO	G GG1	T AAC	CGT	GAG	GTG	AAG	CAG	GCT	GGG	GAA	TAT	CAG	ССТ	GAA	2101
	Cys	Lei	Gly	/ Asn	Arg	Glu	Val	Lys	Gln	Ala	Gly	Glu	Tyr	Gln	Pro	Glu	
5	625	;				630					635	;				640	
	GAA	CAA	CCA	GAA	GCT	GAC	ACT	GAT	TAC	AGC	CGA	GCT	CAG	GAA	GCT	AGG	2149
10	Glu	Gln	Pro	Glu	Ala	Asp	Thr	Asp	Tyr	Ser	Arg	Ala	Gln	Glu	Ala	Arg	
					645					650					655		
	AGG	TTC	ATG	ATC	TAT	GTC	CAC	ACC	AAA	ATG	ATG	ATA	GTT	GAC	GAT	GAG	2197
15	Arg	Phe	Met	lle	Tyr	Val	His	Thr	Lys	Met	Met	He	Val	Asp	Asp	Glu	
				660					665					670			
	TAC	ATC	ATC	ATC	GGT	TCT	GCA	AAC	ATC	AAC	CAG	AGG	TCG	ATG	GAC	GGC	2245
20	Tyr	He	lle	lle	Gly	Ser	Ala	Asn	He	Asn	Gln	Arg	Ser	Met	Asp	Gly	
			675					680					685				
ne.	GCT	AGG	GAC	TCT	GAG	ATC	GCC	ATG	GGC	GGG	TAC	CAG	CCA	TAC	CAT	CTG	2293
25	Ala	Arg	Asp	Ser	Glu	He	Ala	Met	Gly	Gly	Tyr	Gln	Pro	Tyr	His	Leu	
		690					695				•	700					
30	GCG	ACC	AGG	CAA	CCA	GCC	CGT	GGC	CAG	ATC	CAT	GGC	TTC	CGG	ATG	GCG	2341
	Ala	Thr	Arg	Gln	Pro	Ala	Arg	Gly	Gln	lle	His	Gly	Phe	Arg	Met	Ala	
	705					710					715					720	
35	CTG	TGG	TAC	GAG	CAC	CTG	GGA	ATG	CTG	GAT	GAT	GTG	TTC	CAG	CGC	CCC	2389
	Leu	Trp	Tyr	Glu	His	Leu	Gly	Met	Leu	Asp	Asp	Va I	Phe	Gin	Arg	Pro	
					725					730					735		
10	GAG	AGC	CTG	GAG	TGT	GTG	CAG	AAG	GTG	AAC	AGG	ATC	GCG	GAG	AAG	TAC	2437
	Glu	Ser	Leu	Glu	Cys	Val	Gln	Lys	Va ļ	Asn	Arg	He	Ala	Glu	Lys	Tyr	
5				740					745					750			
	TGG	GAC	ATG	TAC	TCC	AGC	GAC	GAC	стс	CAG	CAG	GAC	CTC	CCT	GGC	CAC	2485
	Trp	Asp	Met	Tyr	Ser	Ser	Asp	Asp	Leu	Gln	Gln	Asp	Leu	Pro	Gly	His	
0			755					760					765				
	CTC	CTC	AGC	TAC	CCC	ATT	GGC	GTC	GCC	AGC	GAT	GGT	GTG	GTG	ACT	GAG	2533

	Leu Leu Ser Tyr Pro Ile Gly Val Ala Ser Asp Gly Val Val Thr Glu	
	770 775 780	
5	CTG CCC GGG ATG GAG TAC TIT CCT GAC ACA CGG GCC CGC GTC CTC GGC 25	581
	Leu Pro Gly Met Glu Tyr Phe Pro Asp Thr Arg Ala Arg Val Leu Gly	
10	785 790 795 800	
	GCC AAG TCG GAT TAC ATG CCC CCC ATC CTC ACC TCA TAGACGAGGA AGCACT 26	333
	Ala Lys Ser Asp Tyr Met Pro Pro IIe Leu Thr Ser	
15 [°]	805 810	
	ACACTACAAT CTGCTGGCTT CTCCTGTCAG TCCTTCTGTA CTTCTTCAGT TTGGTGGCGA 26	393
	GATGGTATGG CCGTTGTTCA GAATITCTTC AGAATAGCAG TTGTTACAGT TGTGAATCAT 27	753
20	AAAGTAATAA GTGCAGTATC TGTGCATGGT TGAGTTGGGA AGAAGATCGG GGATGCAATG 28	313
	ATGCTTGTGA AGTTGTGATG CCGTTTGTAA GATGGGAAGT TGGGAACTAC TAAGTAATTG 28	373
	GCATGATTGT ACTITICACT ACTGTTTAGC GTTGTTGATA CTGGTTAACC GTGTGTTCAT 25	933
25	CTGAACTTGA TTCTTGATGC AGTTTGTGGC ATTACCAGTT TATCATCGTT CTTCAGGAAA 25	993
	AAAAAAAAA AAAAAAAAA AAAAAAAAA AAAAAAAA	040
3 <i>0</i>	SEQ ID NO.: 3	
	SEQUENCE LENGTH: 2799	
	SEQUENCE TYPE: Nucleic Acid	
35	SEQUENCE TYPE: Nucleic Acid MOLECULE TYPE: Genomic DNA	
35		
35	MOLECULE TYPE: Genomic DNA	
35 40	MOLECULE TYPE: Genomic DNA ORIGINAL SOURCE	
	MOLECULE TYPE: Genomic DNA ORIGINAL SOURCE ORGANISM: Oryza sativa	60
10	MOLECULE TYPE: Genomic DNA ORIGINAL SOURCE ORGANISM: Oryza sativa SEQUENCE DESCRIPTION CAAGGGTGTA CATAGATTIG TCTCGTAAAA TAGTATTATA ATATTATAAA CITATTACTC	60 1 20
	MOLECULE TYPE: Genomic DNA ORIGINAL SOURCE ORGANISM: Oryza sativa SEQUENCE DESCRIPTION CAAGGGTGTA CATAGATTIG TCTCGTAAAA TAGTATTATA ATATTATAAA CITATTACTC TATCCGTTCT AAAATATAAG AACCTTATGA CTGGATGGAA CATTTCCTAG TACTACGAAT	
10	MOLECULE TYPE: Genomic DNA ORIGINAL SOURCE ORGANISM: Oryza sativa SEQUENCE DESCRIPTION CAAGGGTGTA CATAGATTIG TCTCGTAAAA TAGTATTATA ATATTATAAA CITATTACTC TATCCGTTCT AAAATATAAG AACCTTATGA CTGGATGGAA CATTTCCTAG TACTACGAAT CTGAACACAT GTCTAGATTC ATAGTACTAG GAAATGTCTC ATCGCGGTAC TAGGTTCTTA	1 20
10	MOLECULE TYPE: Genomic DNA ORIGINAL SOURCE ORGANISM: Oryza sativa SEQUENCE DESCRIPTION CAAGGGTGTA CATAGATTIG TCTCGTAAAA TAGTATTATA ATATTATAAA CITATTACTC TATCCGTTCT AAAATATAAG AACCTTATGA CTGGATGGAA CATTTCCTAG TACTACGAAT CTGAACACAT GTCTAGATTC ATAGTACTAG GAAATGTCTC ATCGCGGTAC TAGGTTCTTA TATTTTAGGA TGGAGGGAGT TTAATATAAA ACTAATGGTT AGAACTTTGA AAGTTTGATT	1 20 1 80

TTTCCATCAC	C ATCAACTTG1	CATATACACA	TAACTTTTCA	GTCACATCAT	CCCCAATTTC	420
AACCAAAAT	CAAACTTTGCG	CTGAACTAAA	CACAACCTTT	GGGCCCGTTT	AGTTCCCCAA	480
TTTTTTCCC	CAAAAACATCA	CATCGAATCT	TTGGACACAT	GCATGAAGCA	TTAAATATAG	540
ATAAAAAGAA	AAACTAATTG	CACAGTTATG	GAGGAAATCG	CGAGACGAAT	CTTTTAAGCC	600
TAATTAGTC	GTGATTAGCC	ATAAGTGCTA	CAGTAACCCA	ATTGTGCTAA	TGACGGCTTA	660
ATTAGTOTO	CACAAGATTCG	TCTCGCAGTT	TCCAGGCGAG	TTCTGAAATT	AGTTTTTCA	720
TTCGTGTCCG	AAAACCCCTT	CCGACATCCG	GTCAAACGTT	CGATATGACA	CCCACAAATT	780
TTCTTTTCCC	CAACTAAACA	CACCCTTTAT	CTCTTACCCT	CTGGCTCTTT	CAGTAGGCAT	840
ATCCAAGACA	GCTGGTAATG	CAGGCTCGGA	CATAATTTGA	CAGTTACGTT	CATGTGACCG	900
ACGGTTGATG	CTAGTGCAAC	TGCAACATAC	TGTTCAGATG	GATGTCCCAA	CGAGCTCAAA	960
ACAACTTAGG	TGGCGCGTCG	CGATTCATCA	ATAACTCAAA	TGGAAGCGCA	AGTGCACGTA	1020
CGAAAATGAC	AGCGAGTGAG	GTGGCGAGCC	TCACCTTGGT	GATCCCAACC	GGATAAGCTA	1080
TGCATCAGCC	AGTTTCGTGG	GGCTGCACAT	TTCGTCGAAC	ACCTGGAGTC	CACGCCGCCG	1140
GCGACGTCGG	CACAGCGCGC	CCGCCCACCG	CCCACGCACG	CGCTTGACTC	CACCCATGTT	1200
CTCCCTTCTC	GACGCCCGCG	AAGCCAGCGA	ACCGATCCGA	GGAAGTCAAG	CCCCCACCGC	1260
CACTTGGACC	GACCTCGGGA	CGACGACGCC	CCCGCGCTCT	TCTAGACGCG	CGGACGACGC	1320
GGGCGCTGGC	TCCGCGACGC	GACGTCGCGG	TCATGGAGTA	ACCGCGACGG	ACAGATACTT	1380
CTACCCGTTT	TTAACCTCGC	стсстсстсс	TCCCGGCTCG	AGATCCGTGG	CCACGACGCG	1440
TGGTGGGAAA	CCGGGAACGA	CGTGCACGCA	CGCACACAGG	GCAAGTTTCA	GTAGAAAAAT	1500
CGCCGGCATC	CAGATCGGGA	CAGTCTCTCT	TCTCCCGCAA	TTTTATAATC	TCGCTCGATC	1560
CAATCTGCTC	CCCTTCTTCT	TCTACTCTCC	CCATCTCGGC	TCTCGCCATC	GCCATCCTCC	1620
TCTCCCTTCC	CGGAGAAGAC	GCCTCCCTCC	GCCGATCACC	ACCCGGTAAG	CCCAGTGTGC	1680
TTAGGCTAAG	CGCACTAGAG	CTTCTTGCTC	GCTTGCTTCT	TCTCCGCTCA	GATCTGCTTG	1740
CTTGCTTGCT	TCGCTAGAAC	CCTACTCTGT	GCTGCGAGTG	TCGCTGCTTC	GTCTTCCTTC	1800
CTCAAGTTCG	ATCTGATTGT	GTGTGTGGGG	GGGCGCAGGT	AGGGCGAGGA	GGGAGCCAAA	1860
TCCAAATCAG	CAGCC ATG G	CG CAG ATG	CTG CTC CAT	GGG ACG CT	G CAC GCC	1911
	Met A	la Gin Met	Leu Leu His	Gly Thr Le	u His Ala	

1 5 10

	ACC	ATC	TTC	GAG	GCG	GCG	TCG	CTC	тсс	AAC	CCG	CAC	CGC	GCC	AGC	GGA	1959
-	Thr	He	Phe	Glu	Ala	Ala	Ser	Leu	Ser	Asn	Pro	His	Arg	Ala	Ser	Gly	
5			15					20					25				
	AGC	GCC	CCC	AAG	TTC	ATC	CGC	AAG	GTTC	GGAC	CC 1	TCTC	CTTA	A TO	CTACT	CGTC	2013
10	Ser	Ala	Pro	Lys	Phe	lle	Arg	Lys									
		30					35										
	TTTG	CTCI	TG (стстт	TTTC	T T	TGT	STCCC	: 111	CTTC	TGT	GTGC	CTTT	GC A	ATGAC	CCCGA	2073
15	ATTT	GATO	CTG (CTAGT	GCAC	A GI	ACAG	STCAG	ATA	CACT	GAA	ACGA	ATCT	GA A	ATTO	CTGGAT	2133
	TATT	TAGG/	AAA	ATAA	AGAG	G TA	GTAC	BACAA	GAA	ATTG	AGA	TACT	TTCI	AT (CAAGA	ATTGGT	2193
	CTAT	TATO	CT 1	rggco	CATTI	с ті	GTTI	rgacc	CAA	GTAC	CTTC	TTT	CAAT	CTA (GAGTI	TTGCTG	2253
20	TGT	STGAT	rgt (GTG1	rgtgt	тт	STGTO	CACCA	AAA A	ATC1	TCA	TTAG	CTA	AA (CTGA	AATTTT	2313
	ATTI	TATTA	AAC 1	GAC	CTACT	A A	AAAT	STAGA	GTI	гстст	GTG	TGT	BATGI	GT (CTT	STGTCA	2373
••	CCAA	AAAA	rct 1	GAT?	TGAT	A GA	AGTTI	TTAT	TT	ATTT	ATTA	ACTO	BACCI	TAC 1	TACA	AATCTA	2433
25	TTGC	CTGT	ATG (CTATO	STGTO	T CI	GTAT	CACC	TGA	AAAT	GCAA	TGT	CTTC	TC 1	TTTG	TTGTTC	2493
	TTGA	ATCT	AAC A	ACGTO	GAGC1	C AT	rgtc	AACAG	TT1	r GTC	G GA	G GG	AT1	GA	G GA	CACT	254 7
3 <i>0</i>									Phe	e Val	Gli	. Gly	/ 116	e Gli	u Ası	Thr	
												40					
	GTG	GGT	GTC	GGC	AAA	GGC	GCC	ACC	AAG	GTG	TAT	TCT	ACC	ATT	GAT	CTG	2595
35	Val	Gly	Val	Gly	Lys	Gly	Ala	Thr	Lys	Val	Tyr	Ser	Thr	lle	Asp	Leu	
	45					50					55					60	
	GAG	AAA	GCT	CGT	GTA	GGG	CGA	ACT	AGG	ATG	ATA	ACC	AAT	GAG	ccc	ATC	2643
40	Glu	Lys	Ala	Arg	Val	Gly	Arg	Thr	Arg	Met	He	Thr	Asn	Glu	Pro	lle	
	65					70					75						
	AAC	CCT	CGC	TGG	TAT	GAG	TCG	TTC	CAC	ATC	TAT	TGC	GCT	CAT	ATG	GCT	2691
45	Asn	Pro	Arg	Trp	Tyr	Glu	Ser	Phe	His	He	Tyr	Cys	Ala	His	Met	Ala	
	80					85					90						
50	TCC	AAT	GTG	ATC	TTC	ACT	GTC	AAG	ATT	GAT	AAC	CCT	ATT	GGG	GCA	ACG	2739
	Ser	Asn	Val	lle	Phe	Thr	Val	Lys	lle	Asp	Asn	Pro	lie	Gly	Ala	Thr	

105 95 100 AAT ATT GGG AGG GCT TAC CTG CCT GTC CAA GAG CTT CTC AAT GGA GAG 2787 5 Asn lle Gly Arg Ala Tyr Leu Pro Val Gln Glu Leu Leu Asn Gly Glu 120 110 115 2799 GAG ATT GAC AGA 10 Glu lle Asp Arg 125 15 SEO ID NO.: 4 SEQUENCE LENGTH: 173 SEQUENCE TYPE: Nucleic Acid 20 MOLECULE TYPE: Genomic DNA ORIGINAL SOURCE 25 ORGANISM: Oryza sativa SEQUENCE DESCRIPTION GTAAGCCCAG TGTGCTTAGG CTAAGCGCAC TAGAGCTTCT TGCTCGCTTG CTTCTTCTCC 30 GCTCAGATCT GCTTGCTTGC TTGCTTCGCT AGAACCCTAC TCTGTGCTGC GAGTGTCGCT 120 GCTTCGTCTT CCTTCCTCAA GTTCGATCTG ATTGTGTGTG TGGGGGGGCG CAG 173 35

Claims

40

- 1. An isolated DNA fragment having a nucleotide sequence shown in SEQ ID NO. 1 in Sequence Listing or having a nucleotide sequence which is the same as the nucleotide sequence shown in SEQ ID NO. 1 in Sequence Listing except that one or a plurality of nucleotides are added, inserted, deleted or substituted, the latter nucleotide sequence having a function to promote expression of a gene downstream thereof.
- 2. The DNA fragment according to claim 1, which has a nucleotide sequence shown in SEQ ID NO. 1 in Sequence Listing.
- 3. An isolated DNA fragment having a nucleotide sequence shown in SEQ ID NO. 4 in Sequence Listing or having a nucleotide sequence which is the same as the nucleotide sequence shown in SEQ ID NO. 4 in Sequence Listing except that one or a plurality of nucleotides are added, inserted, deleted or substituted, the latter nucleotide sequence having a function to promote expression of a gene downstream thereof.
- 4. The DNA fragment according to claim 3, which has a nucleotide sequence shown in SEQ ID NO. 4 in Sequence Listing.
 - A recombinant vector comprising said DNA fragment according to claim 1 and a foreign gene to be expressed, which is operably linked to said DNA fragment at a downstream region of said DNA fragment.

- 6. The recombinant vector according to claim 5, wherein said DNA fragment has a nucleotide sequence shown in SEQ ID NO. 1 in Sequence Listing.
- 7. The recombinant vector according to claim 6, wherein said DNA fragment has a nucleotide sequence shown in SEQ ID NO. 4 in Sequence Listing.
 - 8. A method for expressing a foreign gene comprising introducing said recombinant vector according to claim 3 into host cells and expressing said foreign gene.
- 10 9. The method according to claim 8, wherein said DNA fragment has a nucleotide sequence shown in SEQ ID NO. 1 in Sequence Listing.
 - 10. The method according to claim 8, wherein said DNA fragment has a nucleotide sequence shown in SEQ ID NO. 4 in Sequence Listing.

19

15

20

25

30

35

40

45

50




Fig. 1

INTERNATIONAL SEARCH REPORT International application No. PCT/JP96/00812 A. CLASSIFICATION OF SUBJECT MATTER Int. C16 C12N15/11, C12N15/63, C12N15/82, C12N9/16 According to International Patent Classification (IPC) or to both national classification and IPC FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int. C16 C12N15/00, C12N9/16 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE, WPI, WPI/L, BIOSIS PREVIEWS C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Α JP, 03-103182, A (Mitsubishi Kasei Corp.), April 30, 1991 (30. 04. 91) (Family: none) Judy C. et al. "Introns increase gene 1 - 10 Α expression in cultured maized cells" GENE & DEVELOPMENT (1987) Vol. 1, p. 1183-1200 Akira T. et al. "Enhancement of foreign gene 1 - 10 Α expression by a dicot intron in rice but not in tobacco in correlated with an increased level of mRNA and an efficient splicing of the intron' Nucleic Acids Research (1990) Vol. 18, No. 23, p. 6767-6770 PΑ Jun U. et al. "Purification and 1 - 10Characterization of Phospholipase D (PLD) from rice (Oryza sativa L.) and Cloning of cDNA for PLD from Rice and Maize (Zeamays L.) " Plant Cell Physiol. (1995) Vol. 36, No. 5, p. 903-914 Further documents are listed in the continuation of Box C. See patent family annex. later document published after the international filing date or priority date and not in conflict with the application but cited to understand Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance the principle or theory underlying the invention "E" earlier document but published on or after the international filing date "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "O" document referring to an oral disclosure, use, exhibition or other document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report July 2, 1996 (02. 07. 96) June 19, 1996 (19. 06. 96) Name and mailing address of the ISA/ Authorized officer Japanese Patent Office

21

Telephone No.

Facsimile No.

Form PCT/ISA/210 (second sheet) (July 1992)